Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO)

Assistance Publique - Hôpitaux de Paris

Status and phase: Completed; Phase 2

Conditions: Scleroderma Renal Crisis

Treatments: Drug: Bosentan

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01241383

P081217

Details and patient eligibility

About

Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive collagen deposition, autoimmunity and by vascular hyper-reactivity and obliterative microvascular phenomena that involves multiple organs. Scleroderma Renal Crisis (SRC) occurs in 5% of patients and mainly with diffuse cutaneous SSc. The routine use of angiotensin-converting enzyme inhibitors (ACEI) has been reported to dramatically improve outcome, with a fall of the 12-month mortality from 76% to less than 15% in the United-States. Despite prognostic improvement, SRC remains a severe manifestation of SSc and functional outcome and survival remains poor. Bosentan is a specific, orally active, dual endothelin receptor antagonist that has recently been approved for the treatment of primary pulmonary arterial hypertension and for the prevention of ischemic digital ulcers. Bosentan could have therapeutic benefits on others vascular injuries and particularly in SRC.

Full description

Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive collagen deposition, autoimmunity and by vascular hyper-reactivity and obliterative microvascular phenomena that involves multiple organs. Scleroderma Renal Crisis (SRC) occurs in 5% of patients and mainly with diffuse cutaneous SSc. The routine use of angiotensin-converting enzyme inhibitors (ACEI) has been reported to dramatically improve outcome, with a fall of the 12-month mortality from 76% to less than 15% in the United-States. Despite prognostic improvement, SRC remains a severe manifestation of SSc and functional outcome and survival remains poor. Bosentan is a specific, orally active, dual endothelin receptor antagonist that has recently been approved for the treatment of primary pulmonary arterial hypertension and for the prevention of ischemic digital ulcers. Bosentan could have therapeutic benefits on others vascular injuries and particularly in SRC.

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men or women ≥ 18 years
• Patients had to fulfil ACR and/or LEROY et MEDSGER criteria for systemic sclerosis
• Patients had to fulfil criteria for renal systemic sclerosis
• Written informed consent obtained

Exclusion criteria

• Scleroderma renal crisis occuring before the age of eighteen
• Patients who are receiving bosentan within one month of inclusion for pulmonary arterial hypertension or digital ulcers prevention
• Other treatment by selective or nonselective antagonist endothelin receptor
• Left ventricle systolic dysfunction (EF < 40 %)
• Patients with systolic blood pressure < 85mm Hg
• Progressive cancer or considered cured for less than 5 years
• Patients with a known hypersensitivity to bosentan or any of the excipients
• Patients with HIV, HCV, HBV infection
• Patients with Liver disease Child-Pugh B and C
• Patients who are pregnant or breast-feeding
• Women of child-bearing age who are sexually active without practising reliable methods of contraception
• Patients who do not give informed consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

Bosentan

Experimental group

Description:

Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks

Treatment:

Drug: Bosentan